Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07511062 · ClinicalTrials.gov registry record · Phase 1
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
A Phase 1 study, sponsored by Northside Hospital.
- Not yet
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07511062: Clinical Trial Phase 1 study, sponsored by Northside Hospital.
NCT07511062 is a Phase 1 study that has not yet begun recruiting, run by Northside Hospital. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07511062, a Phase 1 study, has not yet begun recruiting, sponsored by Northside Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients
Primary Outcome
To find the recommended phase 2 dose (RP2D) of axatilimab when combined with decitabine and venetoclax by recording adverse events based on the CTCAE v.5.
Interventions
- DRUG Venetoclax
- DRUG Decitabine
- DRUG Axatilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2030-08-01 |
| Phase | Phase 1 |
What is known before NCT07511062 opens enrollment
NCT07511062 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT07511062 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07511062 about?
NCT07511062 is a clinical study titled "Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML". Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients
What is the current status of trial NCT07511062?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-08-01. Estimated completion is 2030-08-01.
What interventions are being tested in trial NCT07511062?
The interventions under investigation include: Venetoclax (DRUG), Decitabine (DRUG), Axatilimab (DRUG).
Who is sponsoring clinical trial NCT07511062?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07511062's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI